Dr Thomas Zilli speaks to ecancer about the EORTC GUCG-1414 phase III PEGASUS randomised trial.

The trial investigates irradiation plus long-term adjuvant androgen deprivation with GnRH antagonist compared to GnRH agonist in patients with very high risk localised or locally advanced prostate cancer.

The study's primary endpoint was PSA response after six months. Results from over 370 patients show no significant differences in outcomes, but antagonists may lower cardiovascular risks, suggesting their consideration for patients with such histories.

The new standard of care now includes a three-year treatment with abiraterone.